Literature DB >> 6100842

Characterization of adenosine receptors in isolated cerebral arteries of cat.

L Edvinsson, B B Fredholm.   

Abstract

The effect of some adenosine analogues and xanthine derivatives were studied on isolated cerebral arteries from cats. The adenosine analogues caused an almost complete relaxation of cerebral arteries contracted by prostaglandin F2 alpha (PGF2 alpha, 30 microM). The order of potency was: 5-N-ethylcarboxamide adenosine (NECA) greater than 2-chloroadenosine greater than adenosine greater than L-N6-phenylisopropyl adenosine (L-PIA). The analogue D-PIA was very weak and its maximum effect was small. NECA and L-PIA enhanced [3H]-cyclic AMP accumulation in [3H]-adenine labelled feline pial vessels with similar absolute and relative potency to their relaxant effects. The relaxant effects of adenosine and of NECA were competitively antagonized by 8-phenyl-theophylline (pA2 = 6.5). The effect of theophylline and enprofylline could not be tested in higher concentrations than 30 or 10 microM because they affected the vessels directly. At these concentrations they were essentially inactive as adenosine antagonists. The non-xanthine phosphodiesterase inhibitor rolipram (0.1 and 100 microM) caused a slight but non-significant potentiation of the relaxant effect of adenosine. The results are compatible with the opinion that adenosine relaxes cerebral vessels by an action on adenosine A2-receptors. The effect may be linked to adenylate cyclase and can be antagonized by 8-phenyl-theophylline.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6100842      PMCID: PMC2045044          DOI: 10.1111/j.1476-5381.1983.tb10052.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  The dilatatory action of adenosine on pial arteries of cats and its inhibition by theophylline.

Authors:  M Wahl; W Kuschinsky
Journal:  Pflugers Arch       Date:  1976-03-11       Impact factor: 3.657

2.  Adenine compounds: cerebrovascular effects in vitro with reference to their possible involvement in migraine.

Authors:  J E Hardebo; L Edvinsson
Journal:  Stroke       Date:  1979 Jan-Feb       Impact factor: 7.914

Review 3.  pA2 and receptor differentiation: a statistical analysis of competitive antagonism.

Authors:  R J Tallarida; A Cowan; M W Adler
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

4.  Influence of initial tension and changes in sensitivity during amine-induced contractions of pial arteries in vitro.

Authors:  L Edvinsson; K C Nielsen; C Owman
Journal:  Arch Int Pharmacodyn Ther       Date:  1974-04

5.  Role of cyclic nucleotides in adenosine-mediated regulation of coronary flow.

Authors:  W R Kukovetz; G Pöch; S Holzmann; A Wurm; I Rinner
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

6.  Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man.

Authors:  L Edvinsson; J E Hardebo; C Owman
Journal:  Circ Res       Date:  1978-01       Impact factor: 17.367

7.  Influence of adenosine and lowered cerebral blood flow on the cerebrovascular effects of theophylline.

Authors:  G Oberdörster; R Lang; R Zimmer
Journal:  Eur J Pharmacol       Date:  1975-02       Impact factor: 4.432

8.  Action of adenosine and adenine nucleotides on dogs' isolated veins.

Authors:  R H Verhaeghe
Journal:  Am J Physiol       Date:  1977-07

9.  Effect of adenosine and dipyridamole on cerebral blood flow.

Authors:  D D Heistad; M L Marcus; J K Gourley; D W Busija
Journal:  Am J Physiol       Date:  1981-05

10.  Adenosine response on pial arteries, influence of CO2 and blood pressure.

Authors:  P C Gregory; D P Boisvert; A M Harper
Journal:  Pflugers Arch       Date:  1980-07       Impact factor: 3.657

View more
  17 in total

1.  Adenosine can mediate its actions through generation of reactive oxygen species.

Authors:  Debebe Gebremedhin; Brian Weinberger; David Lourim; David R Harder
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

3.  Functional evidence for the presence of adenosine A2-receptors in cultured coronary endothelial cells.

Authors:  C Des Rosiers; S Nees
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

4.  Evidence that A2 purinoceptors are involved in endothelium-dependent relaxation of the rat thoracic aorta.

Authors:  R B Rose'Meyer; W Hope
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

5.  Partial antagonistic effect of adenosine on inverse coupling between spreading neuronal activation and cerebral blood flow in rats.

Authors:  Jens P Dreier; Katrin Tille; Ulrich Dirnagl
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

6.  Decreased arterial responsiveness to multiple cyclic AMP-generating receptor agonists in spontaneously hypertensive rats.

Authors:  K Masuzawa; T Matsuda; M Asano
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

Review 7.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

8.  Differential effects of methylxanthines on local cerebral blood flow and glucose utilization in the conscious rat.

Authors:  J J Grome; V Stefanovich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

9.  Vascular actions of purines in the foetal circulation of the human placenta.

Authors:  M A Read; A L Boura; W A Walters
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Adenosine-induced dilatation of the rabbit hepatic arterial bed is mediated by A2-purinoceptors.

Authors:  R T Mathie; B Alexander; V Ralevic; G Burnstock
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.